VENCLYXTO® offers patients with CLL a chance to
BREAK FREE with longer progression-free survival1*†
NOW APPROVED in 1L CLL: VENCLYXTO + obinutuzumab
NOW APPROVED in 1L CLL: VENCLYXTO + obinutuzumab
In 2L+ CLL:
VENCLYXTO + rituximab
*Reduced risk of progression or death vs O+Clb (HR=0.35; 95% CI: 0.23–0.53 [P<0.0001]). Median follow‑up of 28 months. Median PFS not reached in either arm.
†Reduced risk of progression or death vs BR (HR=0.17; 95% CI: 0.11–0.25 [P<0.0001]). Median follow‑up of 23.8 months. Median PFS not reached with VEN+R vs 17 months (15.5–21.6) with BR.
filler
test
CLL14 trial was designed to allow patients to complete treatment in 1 year1*
CLL14 evaluated VENCLYXTO + obinutuzumab vs a standard CIT regimen (obinutuzumab + chlorambucil)
*CLL14 was a multicenter, open-label, phase 3 trial. Treatment complete after twelve 28-day cycles.
†VENCLYXTO 400 mg daily after initial dose-titration period.
‡Obinutuzumab dosing: 100 mg Cycle 1, Day 1, followed by 900 mg on Days 1 or 2; 1000 mg on Days 8 and 15 and Day 1 of subsequent cycles.
§Chlorambucil dosing: 0.5 mg/kg on Days 1 and 15 of each 28-day cycle.
Click here for more information about titration protocols and full dosing.
Select inclusion criteria
- Previously untreated CLL, coexisting medical conditions (total CIRS >6 or CrCl <70 mL/min), age ≥18 years
Select clinical endpoints
- Primary endpoint: INV-assessed PFS||
- Select secondary endpoints: IRC-assessed PFS,|| ORR,¶ CR+CRi,|| PR,|| and MRD negativity# rate at end of treatment
The median follow-up time at the time of the primary analysis was 28 months (range: 0–36 months).
||Assessed using the International Workshop for Chronic Lymphocytic Leukemia (iwCLL) updated National Cancer Institute–sponsored Working Group (NCI-WG) guidelines (2008).
¶ORR=CR+CRi+PR.
#MRD negativity was assessed at the end of treatment. MRD was evaluated using allele-specific oligonucleotide polymerase chain reaction (ASO-PCR). The cutoff for a negative (undetectable) status was <1 CLL cell per 104 leukocytes.
CLL=chronic lymphocytic leukemia; 1L=first line; 2L+=second line + later lines of therapy; O+Clb=obinutuzumab + chlorambucil; HR=hazard ratio; CI=confidence interval; PFS=progression-free survival; BR=bendamustine + rituximab; VEN+R=VENCLYXTO + rituximab; CIT=chemoimmunotherapy; IV=intravenous; CIRS=Cumulative Illness Rating Scale; CrCl=creatinine clearance; INV=investigator; IRC=independent review committee; ORR=overall response rate; CR=complete remission; CRi=complete remission with incomplete marrow recovery; PR=partial response; MRD=minimal residual disease.
VENCLYXTO + obinutuzumab induced deep responses* in the majority of patients1
The median follow-up time at the time of the primary analysis was 28 months (range: 0–36 months).
High rate of complete remission1,2†
More than twice as many patients in the VEN+O arm (50%) had complete remission (CR+CRi) vs the O+Clb arm (23%) (P<0.0001).
- ORR‡ was 85% (95% CI: 79.2–89.2) in the VEN+O arm vs 71% (95% CI: 64.8–77.2) in the O+Clb arm (P=0.0007)
*Deep response as indicated by CR or MRD negativity.
†Assessed 3 months after treatment completion.2
‡ORR=CR+CRi+PR (secondary endpoint).1
High rates of MRD negativity§ in the VEN+O arm1
- Rates of MRD negativity in peripheral blood at the end of combination treatment were 2 times higher in the VEN+O arm (76% [95% CI: 69.2–81.1]) than in the O+Clb arm (35% [95% CI: 28.8–42.0]) (ITT population) (P<0.0001)1,2
space
- Rates of MRD negativity in bone marrow at the end of combination treatment were 3 times higher in the VEN+O arm (57% [95% CI: 50.1–63.6]) than in the O+Clb arm (17% [95% CI: 12.4–22.8]) (ITT population) (P<0.0001)1,2||
§The cutoff for a negative (undetectable) status was <1 CLL cell per 104 leukocytes (secondary endpoint).1
||Per protocol, MRD in bone marrow was to be assessed only in responding patients (CR/CRi and PR).1
VEN+O=VENCLYXTO + obinutuzumab; ITT=intent to treat.
The PFS benefit of VENCLYXTO + obinutuzumab vs O+Clb was sustained at 3-year follow-up1
INV-assessed progression-free survival (primary analysis)
- 1-year PFS estimate: 95% (95% CI: 91.5–97.7) with VEN+O vs 92% (95% CI: 88.4–95.8) with O+Clb
- 2-year PFS estimate: 88% (95% CI: 83.7–95.1) with VEN+O vs 64% (95% CI: 57.4–70.8) with O+Clb
Median follow-up of 28 months (range: 0–36 months; VEN+O: n=216, O+Clb: n=216) (HR=0.35; 95% CI: 0.23–0.53 [P<0.0001]). Median PFS was not reached in either arm.
Use VENCLYXTO + obinutuzumab at the earliest indicated opportunity in your patients with previously untreated CLL1
The information on this page is based on “Fischer K, Al-Sawaf O, Bahlo J, et al; N Engl J Med 2019” supplementary information and is not included in the SmPC. Use of this subset analysis should be evaluated by affiliate Med/Reg review based on local regulations and policy.
VENCLYXTO + obinutuzumab PFS benefit was consistent across subgroups of interest3*
Data cutoff: 17 August 2018.1
*The INV-assessed PFS subgroup analyses were exploratory only, with no reporting of any P values from statistical testing procedures.
TP53=tumor protein 53; IgVH=immunoglobulin heavy-chain variable gene.
[Placeholder for safety balance required by local regulations]
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
I want to find out
more
about VENCLYXTO
I want to receive more information about VENCLYXTO
References: 1. VENCLYXTO Summary of Product Characteristics. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG. <Current SmPC.> 2. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236. 3. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236(suppl appendix).
GR-VNCCLL-200048 -JAN2021